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Quantitative muscle MRI to follow 
up late onset Pompe patients: a 
prospective study
Sebastian Figueroa-Bonaparte1, Jaume Llauger3, Sonia Segovia1,2, Izaskun Belmonte4, 
Irene Pedrosa4, Elena Montiel4, Paula Montesinos5, Javier Sánchez-González5, Alicia Alonso-
Jiménez1, Eduard Gallardo  1,2, Isabel Illa1,2, Spanish Pompe group* & Jordi Díaz-Manera1,2
Late onset Pompe disease (LOPD) is a slow, progressive disorder characterized by skeletal and 
respiratory muscle weakness. Enzyme replacement therapy (ERT) slows down the progression of 
muscle symptoms. Reliable biomarkers are needed to follow up ERT-treated and asymptomatic LOPD 
patients in clinical practice. In this study, 32 LOPD patients (22 symptomatic and 10 asymptomatic) 
underwent muscle MRI using 3-point Dixon and were evaluated at the time of the MRI with several 
motor function tests and patient-reported outcome measures, and again after one year. Muscle MRI 
showed a significant increase of 1.7% in the fat content of the thigh muscles in symptomatic LOPD 
patients. In contrast, there were no noteworthy differences between muscle function tests in the same 
period of time. We did not observe any significant changes either in muscle MRI or in muscle function 
tests in asymptomatic patients over the year. We conclude that 3-point Dixon muscle MRI is a useful 
tool for detecting changes in muscle structure in symptomatic LOPD patients and could become part of 
the current follow-up protocol in daily clinics.
Pompe disease is a genetic disorder characterized by glycogen accumulation in all tissues of the body1. Pompe 
patients are classified as infantile or late onset (LOPD) depending on their age when symptoms first appear. 
LOPD patients have variable clinical presentations, ranging from asymptomatic hyperCKemia to limb girdle and 
respiratory muscle weakness2. Enzymatic replacement therapy (ERT) is indicated for LOPD patients with skeletal 
muscle weakness and/or respiratory involvement3. Several studies have reported motor and respiratory stabiliza-
tion during the first few years of ERT, and even a decrease in the mortality rate4–9. However, it has been suggested 
that ERT does not stop muscle degeneration at the histological level10. Indeed, recently published data have shown 
impairment in muscle and respiratory function after several years of treatment11.
In following up asymptomatic LOPD patients, the main aim is to detect changes in muscle function that could 
support ERT treatment. However, normal muscle function tests do not reveal the integrity of the muscle structure 
of these patients; muscle fiber loss and fatty replacement could have started without yet influencing the results of 
the tests. Moreover, it is questionable whether muscle function tests are precise enough to detect subtle changes, 
and most authors agree that we need reliable non-invasive biomarkers of disease progression12,13.
Quantitative muscle MRI (qMRI) has emerged as a valuable biomarker to follow up the progression of neu-
romuscular disorders14–18. qMRI is a non-invasive tool that quantifies the amount of fat present in a muscle’s 
region of interest (ROI). The total muscle area and remaining muscle tissue can also be calculated16,17. We have 
previously demonstrated that qMRI correlates strongly with common outcome measures used in LOPD19. Our 
main aim was to investigate MRI changes occurring in the muscles of LOPD patients and assess whether qMRI 
was more sensitive to changes after one year than other commonly used motor function tests or patient-reported 
outcome measures (PROMs).
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Results
Description of the cohort. We recruited 32 late onset Pompe disease (LOPD) patients for this study. They 
were classified as symptomatic or asymptomatic depending on the presence of weakness at clinical examination. 
Twenty-two patients were symptomatic and treated with ERT while ten were non-symptomatic and only had 
hyperCKemia. This second group was studied in neuromuscular disorder units because high levels of CKs were 
found in routine blood tests (7 cases) or because they had relatives already diagnosed with Pompe disease (3 
cases). Clinical and genetic data of the patients included in the study are described in Tables 1 and 2. We found 
two pathogenic mutations in all our patients, except for patient 29. That patient, in absence of defined GAA vari-
ants, was diagnosed by biochemical results as GAA deficieny in leucocytes with the values of 0.03 nmol/min/mg 
protein (normal values: 0.15–1 nmol/min/mg protein) and confirmed in fibroblasts with the value of 21.4 nmol/
min/mg protein (normal values 400–600 nmol/min/mg protein).
N Gender
Age at 
study 
(y) Phenotype Mut 1 Mut 2
CK 
(U/l) ERT
Age at 
ERT
Wheelchair 
dependent
Respiratory 
support
1 Female 50 Proximal weakness LL + axial IVS1-13T > G c.1076-1 G > C 251 Yes 47 N N
2 Female 48 Proximal weakness UL and LL + axial + respiratory insufficiency IVS1-13T > G c.2173 C > T 779 Yes 39 Y NIV
3 Female 26 HyperCKemia IVS1-13T > G c.1889-1 G > A 720 No − N N
4 Female 63 Proximal weakness LL + axial IVS1-13T > G c.2600_2604delinsA 311 Yes 59 N N
5 Male 11 HyperCKemia IVS1-13T > G c.573 > A 276 No — N N
6 Female 45 Proximal weakness LL IVS1-13T > G c.1532 C > A 322 Yes 42 N N
7 Female 51 Proximal weakness LL IVS1-13T > G c.236_246del 240 Yes 47 N N
8 Female 59 Proximal weakness LL IVS1-13T > G c.1637A > G 341 Yes 52 N N
9 Female 55 Proximal weakness LL IVS1-13T > G c.2173 C > T 359 Yes 48 N N
10 Male 42 Proximal weakness LL + axial + respiratory insufficiency IVS1-13T > G c.573 C > A 606 Yes 39 N NIV
11 Female 31 Proximal weakness UL and LL + respiratory insufficiency IVS1-13T > G c.1637A > G 391 Yes 24 Y IV
12 Male 47 Proximal weakness LL + respiratory insufficiency c.2173 C > T c.2173 C > T 508 Yes 45 N NIV
13 Male 51 Proximal weakness LL + respiratory insufficiency IVS1-13T > G c.1657C > T 709 Yes 45 N NIV
14 Female 51 Proximal weakness UL and LL + respiratory insufficiency IVS1-13T > G c.1657C > T 458 Yes 46 N NIV
15 Male 22 HyperCKemia IVS1-13T > G c.1781G > A 1268 No — N N
16 Male 49 HyperCKemia c.271 G > A c.2510 G > A 641 No — N N
17 Male 14 HyperCKemia IVS1-13T > G c.573 C > A 660 No — N N
18 Female 65 Proximal weakness LL + respiratory insufficiency c.1781G > A c. 1194 + 5 G > A 68 Yes 64 N N
19 Female 35 Proximal weakness LL IVS1-13T > G c.1 A > T 355 Yes 29 N N
20 Female 40 Proximal weakness LL IVS1-13T > G c.1889-1 G > A 831 Yes — N NIV
21 Female 52 Proximal weakness LL + respiratory insufficiency c.1781G > A c.1194 + 5 G > A 907 Yes 45 N N
22 Male 64
Proximal weakness 
UL + LL + axial + respiratory 
insufficiency
IVS1-13T > G c.2481 + 102_2646 + 31del 430 Yes 57 N NIV
23 Male 8 HyperCKemia IVS1-13T > G c.1889-1 G > A 1077 No — N N
24 Female 57 Proximal weakness LL + respiratory insufficiency IVS1-13T > G c. 1447 G > T 394 Yes 55 N NIV
25 Male 46 Proximal weakness LL IVS1-13T > G c. 1532 C > A 882 Yes 43 N NIV
26 Male 51 Proximal weakness LL IVS1-13T > G c. 1933G > T 952 Yes 51 N NIV
27 Male 51 HyperCKemia IVS1-13T > G c. 1933G > T 432 No — N N
28 Male 43 Proximal weakness LL IVS1-13T > G c. 1408_1410delinsTTT 317 Yes 43 N N
29 Female 54 Proximal UL and axial weakness Not found Not found 275 Yes 48 N N
30 Female 20 HyperCKemia IVS1-13T > G c. 1551 + 1 G > A 928 No — N N
31 Male 50 HyperCKemia IVS1-13T > G c. 1551 + 1 G > A 250 No — N N
32 Female 36 HyperCKemia IVS1-13T > G IVS1-13T > G 230 No — N N
Table 1. Clinical characteristics of the cohort of LOPD patients participating in the study. Normal CK levels 
were lower than 170 U/L. Patients 13 and 14 and patients 26 and 27 were siblings. Respiratory support: NIV 
means non-invasive ventilation while IV means invasive ventilation. UL: Upper limbs, LL: lower limbs, Y: yes, 
N: No.
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Baseline Muscle MRI and muscle function analysis. We focused our attention on the trunk and thigh 
regions because these muscles are the most commonly involved in LOPD19,20. Analysis of 3-point Dixon studies 
showed a higher statistical significance for the fat fraction (FF) in symptomatic compared to asymptomatic LOPD 
patients in all analyzed muscles, except for sartorius and gracillis (Fig. 1C).
Thigh FF was significantly higher in symptomatic than asymptomatic patients (Median: 34.03 vs. 11.07, Mann 
Whitney U test, p = 0.0001). We found strong correlations between muscle function tests and average thigh FF at 
baseline (Table 3). For example, thigh FF correlated with the total MRC lower limb score (p = 0.0001, ρ = −0.89) 
or 6MWT results (p = 0.0001, ρ = −0.68). In contrast, there was a poor correlation between thigh FF and respira-
tory parameters (CVF while seated: p = 0.02, ρ = −0.4; CVF while lying down: p = 0.17, ρ = −0.34), as well as 
with the results of the patient-reported outcome measures (INQoL: p = 0.05, ρ = 0.37). We did not find a strong 
correlation between thigh FF and clinical parameters such as age at baseline (p = 0.03, ρ = 0.48), time from onset 
of symptoms (p = 0.06, ρ = 0.32), or time on ERT (p = 0.013, ρ = 0.52).
One year muscle MRI and muscle function analysis. We repeated muscle function tests, spirometry, 
patient-reported outcome measures and muscle MRI for all patients after one year. In symptomatic patients, 
muscle function tests, spirometry and patient-reported outcomes did not show significant changes from baseline 
to year 1 (Table 4). In contrast, 3-point Dixon images detected a median increase of 1.7% in thigh FF that was 
statistically significant (paired Wilcoxon signed rank test, p = 0.001) (Fig. 2). Changes in FF between baseline and 
year 1 for individual muscles are specified in Table 5.
We studied whether demographic or clinical factors such as sex or age at the start of ERT were associated with 
the increase of thigh FF at year 1. We only found a significant correlation between baseline thigh FF and increase 
of thigh FF at year 1 (Spearman test p = 0.024; ρ = 0.48). The thigh FF value in a single patient is an average value 
of fat present in muscles at different stages of involvement, from mild involvement to complete fat replacement. It 
has recently been shown that the basal status of muscles could influence response to treatment and consequently 
their increase in FF21. For this reason, in an exploratory post-hoc analysis, we decided to study all muscles as 
separate variables. We classified muscles as having mild fatty infiltration when FF at baseline was lower than 30%, 
moderate infiltration when FF at baseline was between 30 and 60%, and severe infiltration when FF at baseline 
was higher than 60%. There were significant differences in the increase in FF between the three groups after 
one year (Kruskal-Wallis, p < 0.0001, Fig. 3). We observed that FF in muscles with less than 30% FF at baseline 
increased less than muscles with FF between 30 and 60% after one year (median +0.28% vs. +2.84%, p < 0.0001). 
In a similar way, FF in muscles with more than 60% FF at baseline increased less than muscles with FF between 30 
and 60% during the same period (median +0.75% vs. +2.84%, p = 0.004).
Muscle FF did not change significantly in asymptomatic LOPD patients. The median change in thigh FF in this 
group was −0.11% (Paired Wilcoxon signed rank test, P = 0.57). We did not find significant changes in muscle 
function tests in this group of patients after the one year follow-up (Table 4).
Patients
ERT treated HyperCKemia p*
Number of patients 22 10
Gender (W) 15, 68.2% 3, 30% 0.06
Age at baseline 51 (45–55) 24 (13.5–49.5) 0.04
Time from onset of symptoms 15 (11–22) —
Time on ERT 4(2–7) —
Walking aids 10 —
Ventilation 11 —
Time to walk 10 meters (s) 7.1 (5.3–8.8) 3.1 (2.7–3.4) 0.001
6 MWT (m) 414.5 (306.2–493.2) 603 (535.2–677.7) 0.0001
Time to climb 4 steps (s) 3.4 (2.3–6.5) 1.5 (1.2-1.9) 0.005
Time to descend 4 steps (s) 2.8 (2.1–4.8) 1.4 (1.1–1.6) 0.007
Timed up & go test (s) 5.7 (3.1–7.9) 4 (2.9–5.4) 0.03
MRC 96 (84–106) 120 (118–120) 0.0001
Myometry 141 (101–231) 342 (215–491) 0.02
MFM-20 (score) 47.5 (43.5–55) 59.5 (57.5–60) 0.0001
CVF seated (%) 79.9 (60.2–88.7) 92 (85.8–103) 0.03
CVF lying (%) 68.5 (39.5–81.7) 85.5 (77.5–92.2) 0.02
Activlim (score) 21 (18–26) 18 (18–24) >0.05
SF36 (score) 56.9 (43.7–69.9) 85.5 (69–90) 0.02
INQoL (score) 39 (23.5–53.9) 2.5 (0.9–18.1) 0.05
Table 2. Demographic and clinical data of symptomatic and asymptomatic Pompe patients included in the 
study. Median value and 25th–75th percentiles are shown for every variable. S: seconds, m: meters. Mann-
Whitney U test was used to compare the groups, except for sex that was studied using Chi square. 
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Discussion
In the present study we show that quantitative muscle MRI using 3-point Dixon is a useful tool for monitoring 
disease progression in patients with late onset Pompe disease. qMRI was more sensitive to the changes over a 
period of one year than other more conventional muscle tests. We analyzed a large cohort of LOPD patients 
Figure 1. Analysis of fat fraction in thigh and trunk muscles in LOPD patients at baseline. (A,B) Show an 
example of how ROIs are drawn to obtain total muscle area and fat fraction in 3-point Dixon images. (C) 
shows the fat fraction calculated for thigh and trunk muscles in symptomatic (red) and asymptomatic (blue) 
patients. The box plot includes the 25th–75th percentile, the mid lines indicate the median, bars are the 5th–95th 
percentiles. *P < 0.05, **P < 0.01 and ***P < 0.001. RF: Rectus Femoris, VL: Vastus Lateralis, Gr: Gracilis, VM: 
Vastus Medialis, Sa: Sartorius, BFSH: Biceps Femoris Short Head, VI: Vastus Intermedius, ST: Semitendinosus, 
AL: Adductor Longus, BFLH: Biceps Femoris Long Head, Pso: Psoas, SM: Semimembranosus, Ps: Paraspinalis, and 
AM: Adductor Major.
Muscle function test p
Spearman Correlation 
coefficient
Muscle function tests
MRC score (all muscles) 0.0001 −0.89
MRC score (lower limbs) 0.0001 −0.91
Myometry score (all muscles) 0.0001 −0.64
Myometry score (lower limbs) 0.0001 −0.65
6MWT 0.0001 −0.68
Time to walk 10 meters 0.0001 0.80
Time to climb 4 steps 0.0001 0.84
Time to descend 4 steps 0.0001 0.75
Timed up & go test 0.021 0.40
MFM-20 0.0001 −0.75
Spirometry
CVF seated 0.022 −0.40
CVF lying 0.17
Patient-reported outcomes
Activlim 0.01 0.43
SF36 total 0.08
SF36 physical 0.004 −0.53
SF36 mental 0.86
INQoL 0.05 0.37
Table 3. Correlation between Thigh fat fraction and muscle function tests, spirometry results and patient-
reported outcomes at baseline visit. Spearman test was used to study whether there was a significant correlation 
between variables. Adjustment for multiple comparisons using Bonferroni correction was applied; p was 
considered significant if lower than 0.003.
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including symptomatic treated patients and asymptomatic patients with hyperCKemia. Our results support the 
addition of qMRI to the protocol currently used to follow up LOPD patients. In the case of treated patients, qMRI 
could be useful for analyzing treatment response. For asymptomatic patients, meanwhile, an increase in fat infil-
tration detected by qMRI, before clinical symptoms are evident, should be taken into account when considering 
ERT or a closer follow-up of progression.
Hereditary myopathies are characterized by slow progression over the years. Skeletal muscle is replaced by fat 
and fibrotic tissue leading to muscle weakness22. However, annual changes in muscle strength and function can 
be subtle and difficult to quantify, and it is not uncommon to find a heterogeneous rate of progression among 
Symptomatic treated patients (baseline 
vs. 12-month follow-up) (n = 22) P value
Asymptomatic patients (baseline vs. 
12-month follow-up) (n = 10) P value
Muscle function tests
MRC total, score 0 (−4; +6) 0.79 0 (0; +1) 0.31
MRC Lower limbs, score 0 (−5; +4) 0.54 0 (0) 0.31
Knee extension (Nm) 10.74 (0; +20.44) 0.19 −0.96 (−18.11; +3.15) 0.40
Knee flexion (Nm) 1.84 (−1.26; +5.97) 0.20 −0.51 (−10.13; +6.43) 0.67
Hip flexion (Nm) 3.97 (−1.7; +9.84) 0.14 −0.75 (−15.1; +3.9) 0.40
Hip extension (Nm) 2 (−0.13; +5.47) 0.08 −4.15 (−16.04; +1.82) 0.40
6-MWT, m 0 (−9.5; +11) 0.96 10 (−24.7; +7.5) 0.48
Time to walk 10 m, seconds 0(−1.44; +0.4) 0.43 −0.1(−2.52; +0.32) 0.91
Time to climb 4 steps, seconds 0 (−0.42; +0.5) 0.77 −0.1 (−0.32; 0) 0.39
Time to descend 4 steps, seconds 0 (−0.35; +1.32) 0.43 −0.05 (−0.12; +0.1) 0.55
Timed up & go test, sec 0.6 (−0.4; +5.2) 0.47 −0.15 (−0.72; +0.97) 0.94
MFM-20, score 0 (−2; +2) 0.63 0 (0; +1) 0.33
Respiratory studies
CVF seated (%) −0.3 (−4; +3) 0.24 0 (−6; +5.77) 0.73
CVF lying (%) 0 (−6.2; +7.62) 0.73 9 (−2; +12) 0.13
Muscle MRI
qMRI Thighs 1.79 (+0.2; +2.4) 0.001 −0.11 (−0.82; +0.4) 0.57
qMRI Paraspinal −0.03 (−2.23; +0.73) 0.34 0 (−1.25; +1.89) 0.77
Patient-reported outcomes
Activlim 33 (+1; +59) 0.81 67.5 (+37.5; +70.2) 0.31
SF36 1.8 (+0.67; +10.73) 0.22 3.28 (+24.84; +10.12) 0.89
INQoL −2.9 (−5.5; +0.73) 0.17 −4.3 (−8.2; +1.1) 0.31
Table 4. Change between baseline and year 1 evaluation in muscle function tests, spirometry, quantitative 
muscle MRI and patient reported outcome measures in symptomatic and asymptomatic LOPD patients. Median 
value and 25th–75th percentiles are shown. Paired Wilcoxon signed rank test was used to find out whether 
the differences observed between baseline and year 1 evaluation were statistically significant. Adjustment for 
multiple comparisons using Bonferroni correction was applied; p was considered significant if lower than 0.002.
Figure 2. Yearly progression in thigh muscle fat replacement in symptomatic LOPD patients. The box plot 
includes the 25th–75th percentile, the mid lines indicate the median, bars are the 5th–95th percentiles. Each dot 
represents one symptomatic LOPD patient. Mann-Whitney U Test, ***P < 0.001.
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Symptomatic treated patients 
(baseline vs. 12-month follow-up) P value
Asymptomatic patients (baseline vs. 
12-month follow-up) P value
Rectus Femoris 0.44 (+0.02; +2.22) 0.04 −1.04 (−1.94–0.19) 0.13
Vastus Lateralis 1.4 (+0.01; +2.99) 0.009 −0.55 (−1.3; +0.22) 0.24
Vastus Medialis 0.22 (−1.04; +2.8) 0.15 0.48 (−1.34; +2.03) 0.44
Vastus Intermedius 1.66 (+0.24; +3.21) 0.001 −0.54 (−1; +0.05) 0.13
Biceps Femoral short head 1.76 (−0.3; +2.78) 0.007 0.01 (−1.23; +2.64) 0.64
Biceps femoral long head 1.2 (−0.2; +3.3) 0.006 0.36 (−0.79; +0.64) 0.64
Adductor Longus 0.04 (−1.6; +1.24) 0.93 −0.2 (−1.62; +1.35) 0.50
Adductor Magnus 0.51 (−0.06; +1.66) 0.053 0.3 (−1.79; +1.03) 0.57
Sartorius 1.03 (−0.85; +2.34) 0.08 −0.97 (−1.38; +1.13) 0.38
Gracillis −0.11 (−2.44; +1.79) 0.73 −0.71 (−1.79; +0.77) 0.44
Semitendinosus 1.17 (0; +3.22) 0.02 −0.45 (−1.9; +0.77) 0.59
Semimembranous 0.6 (−0.61; +3.15) 0.10 1.82 (−0.16; +3.21) 0.02
Total thigh 1.79 (+0.2; +2.4) 0.001 −0.11 (−0.82; +0.4) 0.57
Paraspinal −0.03 (−2.23; +0.73) 0.34 0 (−1.25; +1.89) 0.77
Psoas 0.97 (+0.06; +0.95) 0.02 −0.91 (−3.08; +2.71) 0.67
Table 5. Fat fraction progression in every thigh and trunk muscle after one year of follow-up in symptomatic 
and asymptomatic patients. Median value is shown with 25th–75th percentiles in brackets. Paired Wilcoxon 
signed rank test was used to find out whether the differences observed between baseline and year 1 evaluation 
were statistically significant. Adjustment for multiple comparisons using Bonferroni correction was applied:  
p was considered significant if lower than 0.004.
Figure 3. Yearly progression of fat replacement in individual muscles of symptomatic patients. (A) Each dot 
represents fat fraction calculated in a single muscle. Vertical lines divide muscles based on baseline fat fractions: 
low (green dots, 0–30%), intermediate (red dots, 30–60%) and severe (orange dots, 60–90%). (B) Increase in 
muscle fat replacement related to baseline fat fraction. The box plot includes the 25th–75th percentile, the mid 
lines indicate the median, bars correspond to the 5th–95th percentiles. Black dots are outliers. Kruskal-Wallis 
test, *P < 0.05, **P < 0.01.
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patients. For these reasons, establishing the progression rate of hereditary myopathies is a difficult task. This dif-
ficulty needs to be addressed, especially at present, when several drugs designed to slow down the progression of 
these diseases are being tested in clinical trials23. To keep up with these therapeutic advances, the neuromuscular 
field needs reliable biomarkers to detect subtle changes in muscle structure and function24–26.
qMRI has recently been suggested as a useful tool for following up patients with various neuromuscular dis-
eases13,15,18,27,28. We analyzed the progression of muscle fat infiltration in patients with LOPD over a period of 
one year using a qMRI sequence, the 3-point Dixon, which has been reported to be a valuable outcome measure, 
reproducible and more sensitive to change after a short period of time than muscle function tests17. Our results 
agree with this previous observation. However, in our opinion, 3-point-Dixon has some limitations. Analysis 
of the images is still performed by hand as ROIs are manually drawn on muscle sections, making the evalua-
tion of images a time-consuming task that requires a high degree of expertise and patience. Software that can 
automatically calculate fat fraction on an entire slice stack has been developed, but has not yet been applied to 
neuromuscular disorders29. As fat infiltration is not homogeneous through all the muscle, several slices should 
be analyzed to calculate median fat infiltration. Moreover, the analysis of a new set of images obtained from the 
same patients after a period of time requires internal anatomic landmarks to facilitate the recognition of slices 
that were previously quantified.
This is the largest prospective study using qMRI in LOPD patients reported so far. We analyzed 22 LOPD 
patients treated with ERT in a wide range of clinical situations, from wheelchair-bound patients requiring ven-
tilation, to patients with slight weakness and no major problems in daily activities30,31. Two reports including 
longitudinal data of qMRI imaging from LOPD patients have already been published. Dr. Carlier and collabora-
tors performed a retrospective analysis of 14 LOPD patients treated with ERT and found a significant increase of 
0.9% in FF of all lower limb muscles during a one year period32. The EMBASSY study provided follow-up data 
for 16 LOPD patients using muscle function tests or repeated muscle biopsies33. Five of the 16 patients were also 
followed up using qMRI which included 3-point Dixon. After six months, a mean increase of 0.6% in FF of all leg 
muscles was observed. However, both studies analyzed lower leg muscles, such as tibialis anterior or soleus, that 
are commonly less involved in LOPD, probably reducing the final average increase in FF observed19,20.
Our study also adds new information about the natural progression of pathology in Pompe disease. 3-point 
Dixon imaging quantifies fat infiltration in skeletal muscles, which is a common pathological change observed 
in neuromuscular disorders. In the case of LOPD, the earliest pathological change is the accumulation of glyco-
gen inside lysosomes in the sarcoplasm34. The progressive addition of lysosomes has two consequences. On the 
one hand, there is dysfunction in the contractile properties of the myofiber. On the other, the cellular autophagy 
process is impaired, leading to an accumulation of debris inside the muscle fiber35–37. Eventually, the muscle 
fiber degenerates and dies, and is replaced by fat, which is detectable using muscle MRI. ERT has been shown to 
reduce the accumulation of glycogen in the sarcoplasm and reactivate cellular autophagy, reducing muscle fiber 
loss37. We therefore argue that 3-point Dixon could be useful in following up the progression of muscle fiber 
loss and fatty replacement in LOPD, which is the final consequence of glycogen accumulation in lysosomes. 
However, 3-point Dixon imaging does not identify glycogen, which would be very useful in following up asymp-
tomatic patients for whom muscle fiber necrosis has probably just started or is minimal38. MRI sequences to 
detect glycogen in human tissue have been developed, including (13)C-MR spectroscopy, chemical exchange 
saturation transfer imaging or proton MRS. However, this technology is not routinely available on standard clin-
ical scanners39. MRI sequences commonly used in clinical centers include T1, 3-point Dixon, T2 and STIR40. 
An increase in the STIR signal in muscles from LOPD patients has recently been described, with the suggestion 
that this is related to the presence of water molecules retained by glycogen41. Nevertheless, this increase was not 
detected in all Pompe patients. In a similar way, an increased T2 signal has been described in some muscles in 
Pompe patients32. Although the increase in STIR signal has been related to accumulation of water or edema, the 
increase in T2 signal is not specific and can be observed in muscle fiber necrosis, inflammation, or presence of 
free water42,43. We therefore still need MRI sequences capable of identifying glycogen that can be used in clinical 
settings, and future research should focus on this area.
We detected an average increase in FF of 1.7% in symptomatic ERT treated patients after one year of follow-up. 
In contrast, no functional changes were observed in the same period of time. The increase in FF detected in 
ERT-treated patients is probably not enough to produce a functional change. However, the progressive increase 
of FF could result in a deterioration of muscle function after several years, as has been recently described in 
patients treated with ERT for more than 5 years11. It would be very valuable to identify the ratio of FF increase 
in non-treated symptomatic LOPD patients. One of the limitations of this study is that we had no control group 
including symptomatic non-treated patients, because ERT usually starts soon after patients develop muscle 
symptoms.
The factors that could influence the response of LOPD to ERT are still not known. The majority of muscles 
had a slow, continuous progression despite ERT treatment, which is reminiscent of that observed in other slow, 
progressive muscular dystrophies. We observed that those muscles which were less infiltrated at the basal eval-
uation were the ones that progressed the least. This finding has also been reported by other groups studying 
Pompe disease. In our opinion, this may be due to the fact that in muscles with a certain degree of degeneration, 
autophagic vacuoles accumulate, impairing the transport of the enzyme from the sarcolemma to the lysosomes 
and probably reducing the effect of ERT35–37. However, this rate of progression has also been described in patients 
with facioscapulohumeral muscle dystrophy28, suggesting that a certain amount of baseline damage in skeletal 
muscles can be associated with a more rapid progression of the disease. If this were confirmed, early treatment of 
patients could result in a better and longer-lasting response to drugs, although this should be further investigated 
in a prospective clinical trial21,37. In any case, we think qMRI may play an important role in the early detection of 
fatty infiltration in muscle, which would suggest following up asymptomatic patients more closely.
www.nature.com/scientificreports/
8SCIENTIfIC REPORTS |  (2018) 8:10898  | DOI:10.1038/s41598-018-29170-7
Based on our results, we conclude that qMRI is a very efficient tool for demonstrating the muscular condition 
of Pompe patients from the morphological point of view, and to monitor symptomatic and asymptomatic LOPD 
patients treated or not with ERT in daily clinics. However, its utility in detecting muscle degeneration in short 
therapeutic trials may be questionable.
Methods
Study design and participants. We are conducting a prospective observational study following up LOPD 
patients at the Hospital de la Santa Creu i Sant Pau (HSCSP) in Barcelona. This comprises annual evaluations, 
including muscle function tests, spirometry, quality of life scales and quantitative muscle MRI. This study is reg-
istered in ClinicalTrials.gov with the identifier NCT01914536. The HSCSP ethics committee approved the study 
and all participants signed an informed consent form. All study procedures were performed in accordance with 
Spanish regulations.
Inclusion criteria for the study were: (1) Diagnosis of LOPD based on recommendations recently proposed by 
the European Pompe Consortium; reduced enzymatic activity in leukocytes, fibroblasts or skeletal muscle and/or 
the presence of two mutations in the GAA gene following the diagnostic44; (2) No contraindications to MRI; (3) 
Symptoms of muscle weakness starting after the age of 18; (4) Willingness to complete all muscle function tests, 
respiratory assessment and patient-reported outcomes measures.
All patients were studied by two physiotherapists (I.B. and I.P.) with considerable experience in neuromus-
cular disorders at HSCSP in Barcelona. The physiotherapists evaluated muscle function using the following 
tests: the 6 minute walking test, time to walk 10 meters, timed up-and-go test, time to climb up and down 4 
steps, and the motor function measure-20 item scale (MFM-20)45. Muscle strength was studied using both the 
Muscle Research Council scale (MRC) and hand-held myometry. ACTIVLIM, INQoL and SF-36 were used as 
patient-reported outcome measures46. We obtained forced vital capacity, both seated and lying down, using the 
Carefusion Microlab ML 3500 MK8 spirometer (Carefusion, Yorba Linda, CA, USA).
Patients were classified as symptomatic or asymptomatic. We considered a patient symptomatic when muscle 
weakness was found in clinical examination using the MRC scale, or when Forced Vital Capacity was at less than 
85% of the normal values.
Muscle imaging. All patients were examined in a Philips Achieva XR 1.5 Tesla located at HSCSP. We used 
the same positioning protocol for all patients: a supine position with the legs stretched out, the patella facing 
upwards and the ankles in a neutral position.
Axial 3D 3-point Dixon images were acquired with the following acquisition parameters: TR/TE = 
5.78/1.8, 4 ms, flip angle = 15°, FOV = 520 × 340 × 300 mm, voxel size = 1 × 1 × 3 mm for thighs and 
FOV = 520 × 320 × 200 mm and voxel size = 1.3 × 1.7 × 5 mm for the lower trunk. The acquisition time was 
45 minutes per patient.
Two investigators (S.F-B. and J.D-M.) analyzed 3-point Dixon MR images using the PRIDE (Philips Research 
Image Development Environment) tool. ROIs were manually drawn on five slices of the following muscles: rectus 
femoris, vastus intermedius, vastus lateralis, vastus medialis, adductor magnus, sartorius, gracilis, semitendinosus 
and semimembranosus; on three slices of biceps femoris long head, biceps femoris short head and adductor longus; 
and on two slices for psoas and lumbar paraspinal muscles. We used anatomical landmarks to ensure consistency 
between baseline and year 1 analysis: we took the last slice in which the femoral head was observed as a reference, 
and analyzed muscles every 5 cm along the entire thigh.
For every ROI, the total area and area covered by fat were calculated automatically using the PRIDE tool 
(Fig. 1A,B). The fat fraction coefficient was defined as fat fat water/ +  where fat and water were the image inten-
sity values over the ROI for the fat and water Dixon images respectively. From those two parameters, and assuming 
that water content corresponds mainly to muscle, fat and muscle area were estimated. Accumulative values across 
all slices were also computed and, as a final index, muscle Fat Fraction (FF) was calculated as follows: FF = (muscle 
fat area × 100)/muscle area. Once we obtained the values from every muscle we calculated thigh fat fraction as 
follows: thigh FF = (Sum of fat area of all thigh muscles × 100)/sum of muscle area of all thigh muscles).
The average time to quantify fat fraction in 3-point Dixon images was 60 minutes. A high degree of reliability 
was found between investigators. The IIC coefficient was 0.982 with a 95% confidence interval from 0.977 to 
0.987.
Statistics. We used non-parametric tests for the statistical analysis of the variables. We used the Mann- 
Whitney U test to investigate whether there were significant differences between variables between groups (symp-
tomatic vs. asymptomatic). Agreement between fat fraction measurements in quantitative muscle MRI, taken by 
two different investigators, was measured using the Intraclass Correlation Coefficient (IIC). We used the paired 
Wilcoxon signed rank test to investigate whether there were significant changes in motor function tests, spirom-
etry, quality of life scales and the fat fraction measurements obtained with qMRI between the baseline and year 
1 visit. We used Spearman’s rank correlation (coefficient reported as ρ) to investigate whether there was a corre-
lation between the results of the muscle function tests, spirometry, quality of life scales and the thigh fat fraction 
obtained using qMRI. As we ran multiple correlations, a Bonferroni test was performed to avoid type 1 errors. 
An ROC curve was performed to study whether thigh fat fraction was able to differentiate between symptomatic 
and asymptomatic Pompe patients with high sensitivity and specificity. The results of all statistical studies were 
considered significant if P was lower than 0.05. Statistical studies were performed using IBM SPSS® Statistics 
software version 21.
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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